Cellectis S.A. (CMVLF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 36.21 Million USD | -48.19% |
| 2022 | 69.88 Million USD | -23.67% |
| 2021 | 91.55 Million USD | -12.47% |
| 2020 | 104.6 Million USD | 124.75% |
| 2019 | 46.54 Million USD | 4471.71% |
| 2018 | 1.01 Million USD | 7730.77% |
| 2017 | 13 Thousand USD | -55.85% |
| 2016 | 29.44 Thousand USD | -59.19% |
| 2015 | 72.15 Thousand USD | -97.9% |
| 2014 | 3.43 Million USD | -26.32% |
| 2013 | 4.66 Million USD | 6.69% |
| 2012 | 4.36 Million USD | -93.53% |
| 2011 | 67.51 Million USD | 6174.59% |
| 2010 | 1.07 Million USD | -58.87% |
| 2009 | 2.61 Million USD | 44.12% |
| 2008 | 1.81 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 58.31 Million USD | -1.65% |
| 2024 Q1 | 49.97 Million USD | 41.25% |
| 2023 Q4 | 36.21 Million USD | -48.86% |
| 2023 FY | 36.21 Million USD | -48.19% |
| 2023 Q2 | 86.42 Million USD | 42.0% |
| 2023 Q3 | 70.81 Million USD | -18.07% |
| 2023 Q1 | 60.86 Million USD | -12.91% |
| 2022 Q4 | 69.88 Million USD | -10.73% |
| 2022 Q3 | 78.29 Million USD | -3.37% |
| 2022 FY | 69.88 Million USD | -23.67% |
| 2022 Q1 | 86.85 Million USD | -5.14% |
| 2022 Q2 | 81.02 Million USD | -6.71% |
| 2021 Q1 | 96.71 Million USD | -7.53% |
| 2021 Q4 | 91.55 Million USD | -3.84% |
| 2021 Q2 | 97.9 Million USD | 1.22% |
| 2021 Q3 | 95.21 Million USD | -2.75% |
| 2021 FY | 91.55 Million USD | -12.47% |
| 2020 Q1 | 48.69 Million USD | 4.64% |
| 2020 FY | 104.6 Million USD | 124.75% |
| 2020 Q3 | 98.83 Million USD | 38.22% |
| 2020 Q4 | 104.6 Million USD | 5.84% |
| 2020 Q2 | 71.5 Million USD | 46.83% |
| 2019 Q4 | 46.54 Million USD | 4.66% |
| 2019 Q2 | 45.71 Million USD | 51.04% |
| 2019 Q1 | 30.26 Million USD | 2872.79% |
| 2019 FY | 46.54 Million USD | 4471.71% |
| 2019 Q3 | 44.46 Million USD | -2.72% |
| 2018 Q3 | 209 Thousand USD | -9.52% |
| 2018 Q2 | 231 Thousand USD | -12.83% |
| 2018 Q1 | 265 Thousand USD | 1938.46% |
| 2018 FY | 1.01 Million USD | 7730.77% |
| 2018 Q4 | 1.01 Million USD | 387.08% |
| 2017 Q4 | 13 Thousand USD | -23.53% |
| 2017 Q2 | 20.59 Thousand USD | -8.24% |
| 2017 Q1 | 22.44 Thousand USD | -23.8% |
| 2017 FY | 13 Thousand USD | -55.85% |
| 2017 Q3 | 17 Thousand USD | -17.44% |
| 2016 Q3 | 41.5 Thousand USD | -1.8% |
| 2016 FY | 29.44 Thousand USD | -59.19% |
| 2016 Q2 | 42.26 Thousand USD | -32.19% |
| 2016 Q4 | 29.44 Thousand USD | -29.06% |
| 2016 Q1 | 62.33 Thousand USD | -13.62% |
| 2015 Q3 | 83.26 Thousand USD | -19.31% |
| 2015 Q4 | 72.15 Thousand USD | -13.34% |
| 2015 Q2 | 103.18 Thousand USD | -81.81% |
| 2015 FY | 72.15 Thousand USD | -97.9% |
| 2015 Q1 | 567.22 Thousand USD | -83.48% |
| 2014 Q3 | 3.56 Million USD | -5.69% |
| 2014 Q4 | 3.43 Million USD | -3.65% |
| 2014 Q2 | 3.77 Million USD | -0.99% |
| 2014 Q1 | 3.81 Million USD | -18.1% |
| 2014 FY | 3.43 Million USD | -26.32% |
| 2013 Q2 | 4.58 Million USD | 1.46% |
| 2013 Q1 | 4.52 Million USD | 3.54% |
| 2013 Q4 | 4.66 Million USD | 2.03% |
| 2013 Q3 | 4.56 Million USD | -0.46% |
| 2013 FY | 4.66 Million USD | 6.69% |
| 2012 FY | 4.36 Million USD | -93.53% |
| 2012 Q2 | 3.9 Million USD | 0.0% |
| 2012 Q4 | 4.36 Million USD | 0.0% |
| 2011 FY | 67.51 Million USD | 6174.59% |
| 2011 Q4 | 67.51 Million USD | 0.0% |
| 2010 FY | 1.07 Million USD | -58.87% |
| 2010 Q4 | 1.07 Million USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 FY | 2.61 Million USD | 44.12% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | 2.61 Million USD | 0.0% |
| 2008 Q4 | 1.81 Million USD | 0.0% |
| 2008 FY | 1.81 Million USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -452539.313% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -1962.75% |
| Qrons Inc. | 80 Thousand USD | -45163.931% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -78.275% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -21047.664% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -73.184% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -61649.505% |
| Mesoblast Limited | 100.29 Million USD | 63.895% |
| Marizyme, Inc. | 667.12 Thousand USD | -5327.907% |
| Genus plc | 228.2 Million USD | 84.132% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 78.2% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -656851.107% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -1538.513% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -2481.101% |
| IMV Inc. | 27.39 Million USD | -32.164% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -567.304% |
| MultiCell Technologies, Inc. | 36.43 USD | -99399145.128% |
| ONE Bio Corp. | 592.19 Thousand USD | -6014.702% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 34.886% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -1526.736% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -2847.924% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -6429.354% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -143032.713% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -1807.388% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -11145.697% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.678% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -24040.763% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -21952.401% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -135.842% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -812537.904% |
| Genscript Biotech Corporation | 287.12 Million USD | 87.389% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -28570.286% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -15692.659% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -15665.156% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -338.179% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -13531.918% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -3403203.102% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -24103.046% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -24103.046% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -25581.663% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -363.06% |
| SYBLEU INC | 300 Thousand USD | -11970.382% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -9712.015% |
| International Stem Cell Corporation | 445 Thousand USD | -8037.336% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -344.309% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -7823.664% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -3018.962% |
| PureTech Health plc | 18.25 Million USD | -98.417% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -24040.763% |
| IXICO plc | 275 Thousand USD | -13067.689% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -205.863% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -37.638% |
| CSL Limited | 11.23 Billion USD | 99.678% |